BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET
Company Participants
Vimal Mehta - Founder & CEO
Richard Steinhart - SVP & CFO
Matt Wiley - SVP & Chief Commercial Officer
Robert Risinger - Chief Medical Officer, Neuroscience
Frank Yocca - Chief Scientific Officer
Conference Call Participants
Gregory Harrison - Bank of America
Colin Bristow - UBS
Sumant Kulkarni - Canaccord
Raghuram Selvaraju - H.C. Wainwright
Yatin Suneja - Guggenheim Securities
Samir Devani - Rx Securities
Kambiz Yazdi - Jefferies
Operator
Good morning, and welcome to BioXcel Therapeutics' Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.
Risk factors that may affect future results are detailed in the company's annual report on Form 10-Q for the quarter ended March 31, 2023, which can be found at www.bioxceltheapeutics.com, or on www.sec.gov, and which will be updated in its quarterly report on Form 10-Q for the quarter ended June 30, 2023. As a reminder, today’s conference is being recorded.
Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer; Richard Steinhart, Chief Financial Officer; Matt Wiley, Chief Commercial Officer; Dr. Rob Risinger, Chief Medical Officer of Neuroscience; Dr. Vince O'Neill, Chief R&D Officer of OnkosXcel Therapeutics; and Dr. Frank Yocca, Chief Scientific Officer.
It is now my pleasure to turn the call over to Dr. Mehta, the CEO and Founder of BioXcel Therapeutics. Please go ahead.
Vimal Mehta
Thank you, operator. Welcome, everyone and thank you for joining our call today. Before we begin, I first want to say that the company was dismayed and frustrated by our recent discovery of certain investigator misconduct that occurred during our TRANQUILITY II trial. This summer has not progressed as we had anticipated and we plan to make significant changes to our entire business structure. While I'm deeply disappointed, I'm more determined than ever to continue developing our drug candidates and put BioXcel Therapeutics back in a position to accomplish its core mission.